$1.61 Billion is the total value of Frazier Life Sciences Management, L.P.'s 44 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 30.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| HILLEVAX INC | $163,257,346 | -2.1% | 9,758,359 | 0.0% | 10.15% | -21.0% | ||
| Buy | IMAGO BIOSCIENCES INC | $143,340,092 | +220.5% | 3,987,207 | +34.2% | 8.91% | +158.8% | |
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | $128,526,634 | -22.6% | 8,684,232 | 0.0% | 7.99% | -37.5% | |
| KDNY | Buy | CHINOOK THERAPEUTICS INC | $113,853,646 | +35.8% | 4,345,559 | +1.9% | 7.08% | +9.6% |
| New | NEWAMSTERDAM PHARMA COMPANYordinary shares | $101,822,906 | – | 9,341,551 | +100.0% | 6.33% | – | |
| SNDX | Buy | SYNDAX PHARMACEUTICALS INC | $94,389,927 | +15.1% | 3,708,838 | +8.7% | 5.87% | -7.1% |
| PHAT | PHATHOM PHARMACEUTICALS INC | $94,328,245 | +1.3% | 8,407,152 | 0.0% | 5.86% | -18.2% | |
| KRYS | Sell | KRYSTAL BIOTECH INC | $79,199,165 | +11.6% | 999,737 | -1.8% | 4.92% | -9.9% |
| MIRM | Buy | MIRUM PHARMACEUTICALS INC | $75,272,087 | -6.4% | 3,860,107 | +0.8% | 4.68% | -24.4% |
| VRNA | Buy | VERONA PHARMA PLCsponsored ads | $73,574,764 | +242.9% | 2,815,720 | +34.1% | 4.57% | +176.9% |
| PCVX | Sell | VAXCYTE INC | $67,005,570 | +80.4% | 1,397,405 | -9.7% | 4.17% | +45.7% |
| RYTM | RHYTHM PHARMACEUTICALS INC | $55,153,280 | +18.9% | 1,894,000 | 0.0% | 3.43% | -4.0% | |
| ALLK | ALLAKOS INC | $40,348,640 | +37.6% | 4,792,000 | 0.0% | 2.51% | +11.1% | |
| ANAB | ANAPTYSBIO INC | $27,881,703 | +21.5% | 899,700 | 0.0% | 1.73% | -1.9% | |
| TARS | TARSUS PHARMACEUTICALS INC | $26,205,146 | -14.4% | 1,787,527 | 0.0% | 1.63% | -30.9% | |
| CRNX | CRINETICS PHARMACEUTICALS IN | $25,891,261 | -6.8% | 1,414,823 | 0.0% | 1.61% | -24.8% | |
| REPL | Buy | REPLIMUNE GROUP INC | $25,338,432 | +82.0% | 931,560 | +15.5% | 1.58% | +46.9% |
| COGT | Buy | COGENT BIOSCIENCES INC | $24,381,820 | -21.2% | 2,109,154 | +1.7% | 1.52% | -36.4% |
| ALPN | ALPINE IMMUNE SCIENCES INC | $21,945,314 | +2.1% | 2,985,757 | 0.0% | 1.36% | -17.6% | |
| KALV | Buy | KALVISTA PHARMACEUTICALS INC | $21,894,687 | -4.0% | 3,238,859 | +106.0% | 1.36% | -22.5% |
| GRTS | Sell | GRITSTONE BIO INC | $17,810,101 | +32.3% | 5,162,348 | -1.4% | 1.11% | +6.9% |
| STRO | SUTRO BIOPHARMA INC | $14,353,950 | +45.6% | 1,776,479 | 0.0% | 0.89% | +17.5% | |
| ACAD | ACADIA PHARMACEUTICALS INC | $13,648,821 | -2.7% | 857,338 | 0.0% | 0.85% | -21.4% | |
| SLN | SILENCE THERAPEUTICS PLCads | $13,437,888 | +54.5% | 881,173 | 0.0% | 0.84% | +24.6% | |
| TRVI | Buy | TREVI THERAPEUTICS INC | $12,860,729 | +54.5% | 6,663,590 | +23.3% | 0.80% | +24.8% |
| CERE | CEREVEL THERAPEUTICS HLDNG I | $12,395,220 | +11.6% | 393,000 | 0.0% | 0.77% | -9.8% | |
| MRUS | MERUS N V | $11,548,030 | -22.8% | 746,479 | 0.0% | 0.72% | -37.6% | |
| VECT | New | VECTIVBIO HLDG AG | $11,480,574 | – | 1,333,400 | +100.0% | 0.71% | – |
| RNA | New | AVIDITY BIOSCIENCES INC | $11,095,000 | – | 500,000 | +100.0% | 0.69% | – |
| IMVT | IMMUNOVANT INC | $10,397,222 | +218.1% | 585,759 | 0.0% | 0.65% | +156.3% | |
| TYRA BIOSCIENCES INC | $10,090,254 | -13.5% | 1,327,665 | 0.0% | 0.63% | -30.3% | ||
| BLUE | BLUEBIRD BIO INC | $9,970,038 | +9.3% | 1,440,757 | 0.0% | 0.62% | -11.7% | |
| ARVN | ARVINAS INC | $9,761,174 | -23.1% | 285,331 | 0.0% | 0.61% | -37.9% | |
| PRTA | New | PROTHENA CORP PLC | $7,705,975 | – | 127,900 | +100.0% | 0.48% | – |
| AUTL | AUTOLUS THERAPEUTICS PLCspon ads | $7,119,028 | -11.2% | 3,746,857 | 0.0% | 0.44% | -28.2% | |
| NTLA | INTELLIA THERAPEUTICS INC | $7,106,535 | -37.7% | 203,684 | 0.0% | 0.44% | -49.7% | |
| New | THESEUS PHARMACEUTICALS INC | $6,963,006 | – | 1,398,194 | +100.0% | 0.43% | – | |
| PASG | PASSAGE BIO INC | $5,184,543 | +10.4% | 3,756,915 | 0.0% | 0.32% | -11.0% | |
| New | ZYMEWORKS DEL INC | $4,794,600 | – | 610,000 | +100.0% | 0.30% | – | |
| ACRS | Sell | ACLARIS THERAPEUTICS INC | $4,570,477 | -28.9% | 290,189 | -28.9% | 0.28% | -42.6% |
| EPIX | Sell | ESSA PHARMA INC | $1,524,955 | +20.9% | 605,141 | -12.7% | 0.10% | -2.1% |
| APTX | APTINYX INC | $537,290 | -22.5% | 1,883,244 | 0.0% | 0.03% | -37.7% | |
| New | NEWAMSTERDAM PHARMA COMPANY*w exp 11/22/202 | $434,289 | – | 500,333 | +100.0% | 0.03% | – | |
| NABRIVA THERAPEUTICS PLC | $32,177 | -8.1% | 17,025 | 0.0% | 0.00% | -33.3% | ||
| MTEM | Exit | MOLECULAR TEMPLATES INC | $0 | – | -1,374,047 | -100.0% | -0.08% | – |
| Exit | PARDES BIOSCIENCES INC | $0 | – | -845,636 | -100.0% | -0.12% | – | |
| MGNX | Exit | MACROGENICS INC | $0 | – | -701,631 | -100.0% | -0.19% | – |
| GRCL | Exit | GRACELL BIOTECHNOLOGIES INCsponsored ads | $0 | – | -2,890,102 | -100.0% | -0.72% | – |
| FLACU | Exit | FRAZIER LIFESCIENCES ACQU COunit 12/09/2025 | $0 | – | -1,501,000 | -100.0% | -1.17% | – |
| TCDA | Exit | TRICIDA INC | $0 | – | -2,549,671 | -100.0% | -2.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2023-02-07
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ARCUTIS BIOTHERAPEUTICS INC | 7 | Q3 2023 | 17.0% |
| MIRUM PHARMACEUTICALS INC | 7 | Q3 2023 | 13.6% |
| PHATHOM PHARMACEUTICALS INC | 7 | Q3 2023 | 8.6% |
| KRYSTAL BIOTECH INC | 7 | Q3 2023 | 7.6% |
| SYNDAX PHARMACEUTICALS INC | 7 | Q3 2023 | 6.3% |
| VAXCYTE INC | 7 | Q3 2023 | 4.8% |
| CRINETICS PHARMACEUTICALS IN | 7 | Q3 2023 | 3.1% |
| ALPINE IMMUNE SCIENCES INC | 7 | Q3 2023 | 3.2% |
| TARSUS PHARMACEUTICALS INC | 7 | Q3 2023 | 2.5% |
| KALVISTA PHARMACEUTICALS INC | 7 | Q3 2023 | 2.1% |
View Frazier Life Sciences Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR/A | 2023-02-07 |
| 13F-HR | 2023-02-03 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-16 |
View Frazier Life Sciences Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.